1,757 results match your criteria: "Universite de Versailles Saint Quentin[Affiliation]"

Background: France allows deep sedation for pain relief, but not for euthanasia. In anticipation of an increase in home-based palliative care, the role of general practitioners is central to the design of outpatient palliative care services. This study aimed to describe the knowledge, attitudes, and practices of general practitioners in mainland France regarding palliative and end of life care.

View Article and Find Full Text PDF

Contraceptive Use Measured in a National Population-Based Approach: Cross-Sectional Study of Administrative Versus Survey Data.

JMIR Public Health Surveill

July 2024

Sexual and Reproductive Health and Rights Unit, Institut National d'Etudes Démographiques, Aubervilliers, France.

Background: Prescribed contraception is used worldwide by over 400 million women of reproductive age. Monitoring contraceptive use is a major public health issue that usually relies on population-based surveys. However, these surveys are conducted on average every 6 years and do not allow close follow-up of contraceptive use.

View Article and Find Full Text PDF

Prevalence and socioeconomic factors associated with non-utilization of dental care in Lebanon: A nationwide cross-sectional survey.

Community Dent Oral Epidemiol

December 2024

Inserm U1018, CESP, Soins De Santé Primaire et Prévention, Université de Paris Saclay, Université de Versailles Saint-Quentin-en-Yvelines, Montigny-le-Bretonneux, France.

Objectives: To assess the prevalence of non-utilization of dental care in Lebanon and associated socioeconomic factors and self-care behaviours.

Methods: A nationwide, quantitative, survey-based study was conducted by trained interviewers with Lebanese residents aged ≥18 years between July and September 2019. Univariate analyses were performed using Pearson Chi Square test or the Fisher's exact test followed by a binary logistic regression using the SPSS Version 25.

View Article and Find Full Text PDF

E-Cadherin Mutational Landscape and Outcomes in Breast Invasive Lobular Carcinoma.

Mod Pathol

October 2024

Institut Curie, Women's Cancer Institute, PSL University, Department of Diagnostic and Theranostic Medicine, Paris, France. Electronic address:

Invasive lobular carcinomas (ILC) are characterized by the loss of E-cadherin expression and CDH1 gene inactivation. Diagnostic reproducibility for this tumor type is currently suboptimal and could be improved by a better understanding of its histomolecular and clinical heterogeneity. We have analyzed the relationship between the presence, type, or position of CDH1 mutations, E-cadherin expression, and clinicopathological features (including outcome) in a retrospective series of 251 primary ILC with a long follow-up (median: 9.

View Article and Find Full Text PDF
Article Synopsis
  • A consensus was reached by an international committee on 24 clinical recommendations for managing ocular surface inflammation in glaucoma patients, focusing on diagnosis, prevention, and treatment based on disease severity.
  • A nonanonymous quasi-Delphi process was used, involving expert collaboration and a web-based survey to identify best management practices for ocular surface disease (OSD) and inflammation (OSI) in glaucoma.
  • The results showed unanimous agreement on key recommendations, including the need to investigate OSI in all glaucoma patients and emphasizing the importance of reducing preserved medications to prevent OSI.
View Article and Find Full Text PDF

We quantified the extent to which the association between education and fast walking speed (FWS) is explained by 17 mediators (cardiovascular risk factors/diseases, comorbidities, health behaviours, socio-professional characteristics, cognition), and examined whether mediators interact with education, in favor of a reserve hypothesis. Cross-sectional analyses are based on Constances (population-based study of French adults 45-69y). 3m-FWS was measured using photoelectric cells.

View Article and Find Full Text PDF

Resilience after severe critical illness: a prospective, multicentre, observational study (RESIREA).

Crit Care

July 2024

Laboratoire de Psychologie: Dynamiques Relationnelles Et Processus Identitaires (Psy-DREPI), Université de Bourgogne Franche-Comté, EA7458, Dijon, France.

Background: Critical-illness survivors may experience post-traumatic stress disorder (PTSD) and quality-of-life impairments. Resilience may protect against psychological trauma but has not been adequately studied after critical illness. We assessed resilience and its associations with PTSD and quality of life, and also identified factors associated with greater resilience.

View Article and Find Full Text PDF
Article Synopsis
  • Scientists studied how different types of exercise affect muscle function in mice with a severe form of Duchenne muscular dystrophy (DMD), a muscle disease.
  • They found that running on a treadmill and removing certain muscles helped improve strength in one specific muscle, while other muscles didn't get stronger from running or exercising.
  • The study suggests that controlled exercise, like resistance training with fewer intense contractions, could help people with DMD, but more research is needed.
View Article and Find Full Text PDF
Article Synopsis
  • Amivantamab-lazertinib demonstrated better progression-free survival (PFS) rates than osimertinib in patients with EGFR-mutant advanced non-small-cell lung cancer (NSCLC), particularly benefiting those with TP53 mutations and detectable circulating tumor DNA (ctDNA).
  • A study involving 858 treatment-naive patients showed that amivantamab-lazertinib outperformed osimertinib in various high-risk subgroups, including individuals with baseline liver metastases and those who did not clear ctDNA during treatment.
  • Results indicated significant improvements in median PFS for patients treated with amivantamab-lazertinib across multiple categories, showcasing its potential as a more effective option for managing advanced
View Article and Find Full Text PDF

Aim: The anticholinergic properties of medications are associated with poorer cognitive performance in schizophrenia. Numerous scales have been developed to assess anticholinergic burden and yet, there is no consensus indicating which anticholinergic burden scale is more relevant for patients with schizophrenia. We aimed to identify valid scales for estimating the risk of iatrogenic cognitive impairment in schizophrenia.

View Article and Find Full Text PDF

The tyrosine kinase Inhibitor (TKI) imatinib is approved for the treatment of the chronic phase of chronic myeloid leukemia (CP-CML). Pharmacokinetic studies have highlighted the importance of inter-patient variability on imatinib plasma trough concentrations (ima[C]min). In the OPTIM-imatinib trial, we demonstrated that therapeutic drug monitoring (TDM) is able to improve the molecular response of CP-CML patients treated with imatinib.

View Article and Find Full Text PDF

Amivantamab plus Lazertinib in Previously Untreated -Mutated Advanced NSCLC.

N Engl J Med

October 2024

From the Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine (B.C.C.), Samsung Medical Center, Sungkyunkwan University School of Medicine (S.-H.L.), and the Lung Cancer Center, Asan Medical Center Cancer Institute (S.-W.K.), Seoul, the Department of Hematology-Oncology, Seoul National University Bundang Hospital, Seongnam (J.-S.L.), and the Medical Department, Chungbuk National University Hospital, Cheongju (K.-H.L.) - all in South Korea; the Department of Medical Oncology, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai (S.L.), Harbin Medical University Cancer Hospital, Harbin (B.L.), the Department of Medical Oncology, Huizhou Municipal Central Hospital of Guangdong Province, Huizhou (H.X.), and Jilin Cancer Hospital, Changchun (Y.C.) - all in China; the Medical Oncology Service, Vall d'Hebron Barcelona Hospital Campus-Vall d'Hebron University Hospital, Barcelona (E. Felip), and the Medical Oncology Department, Hospital Regional Universitario de Málaga y Virgen de la Victoria, Institute of Biomedical Research of Malaga, Malaga (V.G.C.) - both in Spain; Virginia Cancer Specialists, Fairfax (A.I.S.); Institut Curie, Institut du Thorax Curie-Montsouris, Paris (N.G.), and Paris-Saclay University, Université de Versailles Saint-Quentin-en-Yvelines, Versailles (N.G.), and Paris-Saclay University and Institut Gustave Roussy, Villejuif (B.B.) - all in France; the National Cancer Institute, Kyiv, Ukraine (Y.O.); the Division of Medical Oncology, Department of Medicine, Siriraj Hospital Faculty of Medicine, Mahidol University Bangkok Noi Campus, Bangkok, Thailand (P.D.); the Clinical Oncology Unit, Faculty of Medicine, University of Malaya, Kuala Lumpur (A.A.), and the Department of Internal Medicine, Division of Respiratory Medicine, International Islamic University Malaysia Medical Specialist Center, Pahang (S.-H.H.) - both in Malaysia; British Hospital of Buenos Aires, Central British Hospital, Buenos Aires (E.K.); the Department of Medical Oncology, Barretos Cancer Hospital, São Paulo (J.M.D.); the School of Medicine and Institute of Medicine, Chung Shan Medical University, and the Division of Pulmonary Medicine, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung (G.-C.C.), and the Department of Medical Oncology, National Taiwan University Cancer Center, Taipei (J.C.-H.Y.) - both in Taiwan; the Department of Thoracic Oncology, Kansai Medical University Hospital, Hirakata (H.Y.), and the Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka (H.H.) - both in Japan; the Department of Thoracic Oncology, Thoraxklinik, Heidelberg University Hospital, and the National Center for Tumor Diseases Heidelberg, German Center for Lung Research, Heidelberg, Germany (M.T.); City of Hope National Medical Center, Duarte (D.N.), Chao Family Comprehensive Cancer Center, University of California, Irvine, School of Medicine, Orange (S.-H.I.O.), and Janssen Research and Development, San Diego (E. Fennema, D.M., S.M.S.) - all in California; St. John of God Murdoch Hospital, Murdoch, WA, Australia (S.M.); the Department of Medical Oncology, Division of Adult Solid Tumor, Tata Memorial Center and Homi Bhabha National Institute, Mumbai, India (K.P.); the Local Health Unit Authority of Romagna, Ravenna Hospital and Department of Onco-Hematology, Santa Maria delle Croci Hospital of Ravenna, Ravenna (M. D'Arcangelo), and the Division of Thoracic Oncology, European Institute of Oncology IRCCS, Milan (F.M., A.P.) - both in Italy; Health Pharma Professional Research, Mexico City (J.A.-A.), Oncología Médica, Antiguo Hospital Civil de Guadalajara "Fray Antonio Alcalde," Guadalajara, and Universidad de Guadalajara, Guadalajara (J.C.V.L.) - all in Mexico; Instituto Português de Oncologia do Porto, Porto, Portugal (S.A.); Moscow City Oncology Hospital No. 62 (D.S.) and the Medical Center in Kolomenskoe (M.P.) - both in Moscow; the Department of Medical Oncology, Ankara Bilkent City Hospital and Ankara Yıldırım Beyazıt University (M.A.N.Ş.), and the Department of Medical Oncology, Gazi University Faculty of Medicine (O.Y.) - both in Ankara, Turkey; the Department of Medical Oncology, Christie NHS Foundation Trust and Division of Cancer Sciences, University of Manchester, Manchester, United Kingdom (R.C.); the Division of Hematology-Oncology, Henry Ford Cancer Institute, Henry Ford Health, Detroit (S.M.G.); Janssen Research and Development, Raritan, NJ (J.X., T.S., M.M., M. Daksh, M.B.); Janssen Research and Development, Spring House, PA (M.E., R.I., P.L., S. Shah, J.M.B., S. Sethi, R.E.K.); and Johnson and Johnson Clinical Innovation, Campus Basel, Allschwil, Switzerland (I.L.).

Article Synopsis
  • - The study investigates the effectiveness of amivantamab plus lazertinib compared to osimertinib in treating patients with advanced non-small-cell lung cancer (NSCLC) caused by specific genetic mutations.
  • - Results showed that patients receiving the amivantamab-lazertinib treatment had a significantly longer progression-free survival (23.7 months) than those on osimertinib (16.6 months), and the response rate was similar among both groups.
  • - Side effects primarily related to treatment were noted, but the overall survival analysis indicated a potential benefit for amivantamab-lazertinib over osimertinib, with fewer serious complications leading to treatment discontinuation.
View Article and Find Full Text PDF

Background: The COVID-19 pandemic related to SARS-CoV-2 virus was responsible for global pandemic. The severe form of the disease was linked to excessive activation of immune pathways together with a systemic cytokine storm response and thrombotic venous or arterial complications. Factors predicting severe outcomes including venous and/or pulmonary thrombosis (VT) and death were identified, but the prognostic role of their combination was not addressed extensively.

View Article and Find Full Text PDF

Nb-doped SnO(NTO) thin films were synthesized by atomic layer deposition technique at low temperature (100 °C). For an efficient incorporation of the Nb atoms, i.e.

View Article and Find Full Text PDF

[Not Available].

Rev Infirm

June 2024

École régionale des infirmiers anesthésistes Poissy Saint-Germain-en-Laye, UFR Simone-Veil - Santé, Université de Versailles Saint-Quentin-en-Yvelines, 2 avenue de la Source-de-la-Bièvre, 78180 Montigny-Le-Bretonneux, France. Electronic address:

View Article and Find Full Text PDF

Brexucabtagene autoleucel in relapsed or refractory mantle cell lymphoma, intention-to-treat use in the DESCAR-T registry.

Haematologica

November 2024

Service d'hématologie, Institut Curie, Saint Cloud, France ; Université de Versailles Saint-Quentin (UVSQ), France; Laboratoire d'Imagerie Translationnelle en Oncologie (LITO), U1288 Inserm/Institut Curie Centre de recherche.

View Article and Find Full Text PDF
Article Synopsis
  • Two new enzyme replacement therapies for late-onset Pompe disease received approval from the European Medicines Agency between 2022 and 2023, prompting an update to treatment guidelines by the European Pompe Consortium (EPOC).
  • The EPOC, consisting of 25 experts from eight countries, developed a consensus on when to start, switch, or stop ERT based on in-person meetings and discussions.
  • Recommendations emphasize starting ERT in symptomatic patients, criteria for switching treatments based on muscle function stabilization, and the option of stopping ERT if there are severe reactions or lack of improvement, with regular assessments every six months to monitor progress.
View Article and Find Full Text PDF
Article Synopsis
  • Sleep health involves various factors, including personal behaviors and disorders, and symptom network analysis helps visualize the interactions between these factors and how they relate to age and sex.
  • The study analyzed data from over 35,000 participants in France, focusing on sleep-related symptoms using a network approach to compare differences based on age and sex.
  • Results showed that the most central symptoms across all groups were nonrestorative sleep and excessive daytime sleepiness, with younger individuals (especially women) showing additional issues like circadian misalignment and sleep deprivation, while older participants highlighted problems like leg sensory disturbances.
View Article and Find Full Text PDF

Gonadotropic status in adult women with pituitary stalk interruption syndrome.

Eur J Endocrinol

June 2024

Department of Endocrinology, Diabetology and Nutrition, Ambroise Paré University Hospital, Assistance Publique-Hôpitaux de Paris, F-92100 Boulogne Billancourt, France.

Objective: Pituitary stalk interruption syndrome (PSIS) is a rare cause of congenital hypopituitarism. Limited data exist on the gonadotropic status and fertility of adult women with PSIS. Our study aims to describe pubertal development and the evolution of gonadotropic function and fertility in adult women with PSIS.

View Article and Find Full Text PDF

We investigate the static properties of a new class of 1D Ising-like Hamiltonian for binuclear spin-crossover materials accounting for two-, three-, and four-body short-range interactions between binuclear units of spins and . The following 2-, 3-, and 4-body , , and terms are considered, in addition to intra-binuclear interactions, such as effective ligand-field energy and exchange-like coupling. An exact treatment is carried out within the frame of the transfer matrix method, leading to a 4×4 matrix from which, we obtained the thermal evolution of the thermodynamic quantities.

View Article and Find Full Text PDF

[How to interpret and pursue a prolonged quick time or APTT].

Rev Med Interne

September 2024

Service d'hématologie-immunologie-transfusion, hôpital Ambroise-Paré, AP-HP, 9, avenue Charles-de-Gaulle, 92104 Boulogne-Billancourt cedex, France.

The standard hemostasis workup [quick time (QT), and activated partial thrombin time (APTT)] is very commonly prescribed but its interpretation is often difficult for practitioners who are not specialized in hemostasis. Here, we review the principles of the diagnostic approach to these tests. Only a very basic knowledge of the coagulation cascade is necessary to identify which clotting factor tests to prescribe and to interpret the results.

View Article and Find Full Text PDF

Room Temperature Reduction of Nitrogen Oxide on Iron Metal-Organic Frameworks.

Adv Mater

August 2024

Institute of Porous Materials from Paris, Ecole Normale Supérieure, ESPCI Paris, CNRS, PSL University, Paris, 75005, France.

Nitrogen oxides represent one of the main threats for the environment. Despite decades of intensive research efforts, a sustainable solution for NO removal under environmental conditions is still undefined. Using theoretical modelling, material design, state-of-the-art investigation methods and mimicking enzymes, it is found that selected porous hybrid iron(II/III) based MOF material are able to decompose NO, at room temperature, in the presence of water and oxygen, into N and O and without reducing agents.

View Article and Find Full Text PDF

Defining homogeneous subgroups of bipolar disorder (BD) is a major goal in personalized psychiatry and research. According to the neurodevelopmental theory, age at onset may be a key variable. As potential trait markers of neurodevelopment, cognitive and functional impairment should be greater in the early form of the disease, particularly type 1 BD (BD I).

View Article and Find Full Text PDF